Faculty Opinions recommendation of The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
0
Citation
0
Reference
10
Related Paper
Keywords:
Triple-negative breast cancer
<p>Patterns of recurrence in triple negative breast cancer (TNBC) and non-TNBC patients</p>
Triple-negative breast cancer
Triple negative
Cite
Citations (0)
Triple negative breast cancer (TNBC) is a special type of breast cancer.Its special clinical pathological characteristic and molecule expression type make the treatment of TNBC become an international problem.In recent years,a variety of attempts and explorations to the treatment of TNBC have made some initial results,which provides a direction for the treatment of TNBC and offers hope for the patients with TNBC.
Key words:
Breast neoplasms; Combined modality therapy; Triple-negative
Triple-negative breast cancer
Triple negative
Modality (human–computer interaction)
Cite
Citations (0)
Abstract Objective: The objective of this study was to compare ultrasound features and establish a predictive nomogram for distinguishing between triple-negative breast cancer (TNBC) and non-triple-negative breast cancer (non-TNBC). Materials and Methods: The study included a total of 205 patients with confirmed TNBC and 574 patients with non-TNBC, randomly divided into a training set and a validation set at a ratio of 7:3. All patients underwent ultrasound examination and received a confirmatory pathological diagnosis. Nodules were classified according to the Breast Imaging-Reporting and Data System (BI-RADS) standard. Subsequently, the study conducted a comparative analysis of clinical characteristics and ultrasonic features. Results: A statistically significant difference was observed in multiple clinical and ultrasonic features between TNBC and non-TNBC. Specifically, in the logistic regression analysis conducted on the training set, indicators such as posterior echo, lesion size, presence of clinical symptoms, margin characteristics, internal blood flow signals, halo, and microcalcification were found to be statistically significant ( P <0.05). These significant indicators were then effectively incorporated into a static and dynamic nomogram model, demonstrating high predictive performance in distinguishing TNBC from non-TNBC. Conclusion: The results of our study demonstrated that ultrasound features can be valuable in distinguishing between TNBC and non-TNBC. The presence of posterior echo, size, clinical symptoms, margin, internal flow, halo and microcalcification were identified as predictive factors for this differentiation. Microcalcification, hyperechoic halo, internal flow, and clinical symptoms emerged as the strongest predictive factors, indicating their potential as reliable indicators for identifying TNBC and non-TNBC.
Triple-negative breast cancer
Triple test
Triple negative
Nomogram
Cite
Citations (0)
BACKGROUNDTriple-negative breast cancer patients have no expression of Oestrogen Receptor (ER), Progesterone Receptor (PR) and there is neither expression nor amplification of human epidermal growth factor receptor 2 in a tumour.But non-triple negative breast cancer patients have either oestrogen receptor or progesterone receptor or both positive with or without amplification of Human epidermal growth factor receptor 2 in a tumour.The purpose of this retrospective study is to compare and analyse the clinico-pathological features, recurrence, metastasis and prognosis of triple-negative breast cancer patients and non-triple negative breast cancer patients. MATERIALS AND METHODSA retrospective descriptive study for a total of 200 stage III female breast cancer patients (100 triple-negative patients and 100 non-triple-negative patients) were diagnosed and treated at the Department of Radiotherapy, T.D Medical College Hospital, Alappuzha from January 1 st 2011 to December 31 st 2011.The clinical features, recurrence, metastasis and prognosis of the two groups were compared. RESULTSThe triple-negative breast cancer patients were characterised as younger age, higher histological grade, bigger tumour size, higher clinical stage at diagnosis, more recurrence and metastasis, lower 5-year disease free survival rate and 5-year overall survival rate.The lungs, liver and brain were the first three most common sites of metastases. CONCLUSIONIn our study, we found that triple-negative breast cancer was a distinct subgroup of breast cancer with particular clinico-pathologic behaviour.Compared with the non-triple-negative breast cancer, triple-negative breast cancer was characterised by more aggressive behaviour, metastasis tendency and lower disease-free survival and overall survival rate.This result suggested that characteristics like family history, premenopausal status, tumour size, histological grade of triple-negative breast cancer patients had more local relapse and metastases than that of in non-triple-negative breast cancer that was statistically significant.
Triple-negative breast cancer
Triple negative
Cite
Citations (0)
Statement of RetractionWe, the Editors and Publisher of the journal Cell Cycle, have retracted the following article:Bofan Yu, Wei You, Guang Chen, Yang Yu, and Qinheng Yang. MiR-140-5p inhibits cell proliferation and metastasis by regulating MUC1 via BCL2A1/ MAPK pathway in triple negative breast cancer. Cell Cycle. 2019;18(20):2641–2650. doi: 10.1080/15384101.2019.1653107Since publication, concerns have been raised about the integrity of the data in the article. When approached for an explanation, the authors have been unable to address all the concerns raised and have not been able to provide all their original data. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed. The authors have agreed to retract the article.We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.
Triple-negative breast cancer
MUC1
Cite
Citations (25)
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor outcome. Because of lacking therapeutic targets, chemotherapy is the main treatment option for patients with TNBC. Overexpression of HDACs correlates with tumorigenesis, highlighting the potential of HDACs as therapeutic targets for TNBC. Here we demonstrate that trichostatin A (TSA, a HDAC inhibitor) selectively inhibits the proliferation of TNBC cell lines HCC1806 and HCC38 rather than a normal breast cell line MCF10A. The inhibition of TNBC by TSA is via its roles in inducing cell cycle arrest and apoptosis. TSA treatment leads to decreased expression of CYCLIN D1, CDK4, CDK6 and BCL-XL, but increased P21 expression. Moreover, combination of TSA with doxorubicin has synergistic effects on inhibiting proliferation of HCC1806 and HCC38 cells. Our studies identified a promising epigenetic-based therapeutic strategy that may be implemented in the therapy of fatal human breast cancer.
Triple-negative breast cancer
Trichostatin A
Cyclin-dependent kinase 6
Cite
Citations (17)
The management of patients with advanced breast cancer is becoming increasingly complex compared to the past, mainly due to numerous therapeutic innovations introduced in the current therapeutic scenario. At the time of metastatic disease diagnosis, as indicated by the guidelines, it is important to perform a biopsy of the metastatic sites to optimize choices and expand therapeutic options. Approximately 25-45% of patients who experience a recurrence of the primary tumor lose hormone receptor expression: in this context, solid data comes from a subanalysis of the randomized clinical trial ASCENT, in which the benefit of a treatment with antibody-drug conjugate sacituzumab govitecan is also confirmed in case of non-triple negative breast cancer at diagnosis that subsequently convert to a triple negative subtype. The case reported below is representative of this clinical situation.
Triple-negative breast cancer
Triple negative
Triple bond
Cite
Citations (0)
Prognostication of breast cancer using clinico-pathologic variables, although useful, remains imperfect. Recent research has focused on finding new markers of prognosis using gene expression profiling. Panels of proteins assessed by immunohistochemistry might also be useful in this regard. This study focused on Bcl-2 protein expression in triple-negative (TNBC) and non- triple-negative breast cancer (non-TNBC) with correlation to clinico-pathologic variables.We analyzed Bcl-2 expression in 77 women with primary breast carcinoma divided into two groups; triple-negative and non- triple-negative according to expression of estrogen (ER), progesterone (PR) and human epidermal growth factor receptors (Her2/neu). Bcl-2 expression was assessed in relation to age, histo-pathological subtype, grade, nodal status and tumor size.Bcl-2 was expressed in 74% of triple-negative breast cancers and 70% of non- triple-negative cancers. In TNBC, expression was significantly correlated with invasive ductal subtype, while in non-TNBC it was significantly correlated with age and negative nodal status. In both groups higher Bcl-2 expression associated with favourable prognostic factors in breast cancer, but no significant statistical correlations were found.Frequency of Bcl-2 expression does not differ between TNBC and non-TNBC, but different prognostic factors correlate with Bcl-2 in the two cases.
Triple-negative breast cancer
Triple negative
Cite
Citations (8)
Triple-negative breast cancer
Triple negative
Triple test
Cite
Citations (0)
Purpose: Triple negative breast cancer (estrogen receptor-negative, progesterone receptor-negative, and HER2/neu negative) is associated with high risk of recurrence and poor prognosis. We investigated the characteristics and prognosis of triple negative early-stage breast cancer. Methods: We reviewed the records of 821 early-stage breast cancer patients treated at our hospital from 1995 to 2005. We studied the differences between a triple negative group compared with a non-triple negative group. Results: Of 821 early-stage breast cancer patients, 200 (24.4%) were classified as triple negative. Large tumors (＞2 cm) in the triple negative group were significantly more than those in the non-triple negative group (P=0.042). Histologic and nuclear grade of the triple negative group were significantly higher than those of the non-triple negative group (P＜0.001). The median follow-up time is 50 months (1∼135). There have been 50 local recurrences, 98 distant metastases, and 65 deaths. There were high rates of local recurrence in the triple negative group but no difference in 5-year disease free survival rates (P=0.178). The 5-year overall survival rate showed 85% in the triple negative group but 92.8% in the non-triple negative group (P=0.008). The relative risk for overall survival was 1.93 times higher in the triple negative group. Conclusion: Triple negative breast cancer patients in early stages have poor pathologic findings and prognoses. Careful treatment and follow-up are important and further investigation is necessary for triple negative breast cancer.
Triple-negative breast cancer
Triple negative
Triple test
Cite
Citations (3)